SMC Rejects Pregabalin for Nerve Pain
The Scottish Medicines Consortium has completed an appraisal following a re-submission for Lyrica (Pregabalin).
They have concluded that based on current data clinical and cost effectiveness has not been demonstrated for patients who fail to respond to current treatments.
Action: Continue using conventional therapies for the treatment of pain caused by peripheral damage to nerves. Do not use Pregabalin when other treatments fail.
| « SMC Restricts Cymbalta in Major Depression | Consider Compliance in Treatment Failure » |
Bookmark in del.icio.us